HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

olodaterol

a beta1-adrenoceptor agonist; structure in first source
Also Known As:
6-hydroxy-8-(1-hydroxy-2-((2-(4-methoxyphenyl)-1,1-dimethylethyl)amino)ethyl)-2H-1,4-benzoxazin-3(4H)-one; BI 1744 CL; BI-1744 CL
Networked: 38 relevant articles (7 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Hamilton, Alan: 9 articles (10/2015 - 01/2014)
2. Korducki, Lawrence: 9 articles (10/2015 - 01/2014)
3. Abrahams, Roger: 5 articles (10/2015 - 01/2014)
4. Grönke, Lars: 5 articles (10/2015 - 04/2015)
5. Fležar, Matjaž: 5 articles (06/2015 - 01/2015)
6. Tetzlaff, Kay: 4 articles (10/2015 - 04/2015)
7. Bjermer, Leif: 4 articles (10/2015 - 04/2015)
8. Ferguson, Gary T: 4 articles (10/2015 - 01/2014)
9. McGarvey, Lorcan: 3 articles (10/2015 - 04/2015)
10. Waitere-Wijker, Stella: 3 articles (09/2015 - 04/2015)

Related Diseases

1. Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving usual-care background therapy. "
10/01/2015 - "This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2-4) chronic obstructive pulmonary disease (COPD). "
05/01/2015 - "This Phase II, multicentre, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study evaluated four doses of once-daily olodaterol over 4 weeks in patients with chronic obstructive pulmonary disease (COPD), based on efficacy, safety and pharmacokinetic parameters. "
05/01/2015 - "A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease."
05/01/2015 - "This randomised, double-blind, four-way, crossover, Phase II study compared the 24-h forced expiratory volume in 1 s (FEV1) profile of alternative dosing frequencies of two total daily doses of olodaterol (5 and 10 μg) in patients with chronic obstructive pulmonary disease (COPD). "
2. Asthma (Bronchial Asthma)
3. Pneumonia (Pneumonitis)
4. Cough
5. Dyspnea (Shortness of Breath)

Related Drugs and Biologics

1. tiotropium (Spiriva)
2. Citric Acid (Citrate)
3. formoterol (Oxis)
4. Gold
5. 5- (2- (5,6- diethylindan- 2- ylamino)- 1- hydroxyethyl)- 8- hydroxy- 1H- quinolin- 2- one
6. Adrenal Cortex Hormones (Corticosteroids)
7. maleic acid (maleate)
8. 4- (2- ((6- ((2- (((2,6- dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)- 1- hydroxyethyl)- 2- (hydroxymethyl)phenol
9. Bronchodilator Agents (Bronchodilators)
10. Sirolimus (Rapamycin)

Related Therapies and Procedures

1. Nebulizers and Vaporizers (Inhaler)